The Pune-based Serum Institute of India (SII) will launch Covavax its vaccine for children aged above 3 years in the next six months, SII CEO Adar Poonawalla said here on Tuesday.Covavax is currently under trial and has shown excellent .
SII vaccine for 3+ kids by mid-2022, says Adar Poonawalla morungexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morungexpress.com Daily Mail and Mail on Sunday newspapers.
SII CEO Adar Poonawalla announced the launch of Covavax, a covid vaccine for children above 3 years of age. A billion-dollar has been invested in the development of Covid-19 vaccines and the supply chain has outmatched the demand globally.
The Pune-based Serum Institute of India (SII) will launch Covavax its vaccine for children aged above 3 years in the next six months, SII CEO Adar Poonawalla said here on Tuesday.
The pharma regulator's Subject Expert Committee (SEC) has recommended that Bharat Biotech's Covaxin be approved for emergency use in children aged 2 to 18.
The SEC has submitted its proposal for final clearance to the Drugs Controller General of India (DCGI).